INMB - INmune Bio Inc
IEX Last Trade
6.6
-0.260 -3.939%
Share volume: 110,251
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$6.86
-0.26
-3.79%
Fundamental analysis
20%
Profitability
25%
Dept financing
8%
Liquidity
52%
Performance
11%
Performance
5 Days
-4.75%
1 Month
-19.85%
3 Months
-30.57%
6 Months
-43.99%
1 Year
-16.83%
2 Year
-21.47%
Key data
Stock price
$6.60
DAY RANGE
N/A - N/A
52 WEEK RANGE
$6.41 - $14.74
52 WEEK CHANGE
-$0.21
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO:
Region: US
Website: inmunebio.com
Employees: 14
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: inmunebio.com
Employees: 14
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. inkmune, the company’s lead product, primes patient’s nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells’ ability to eliminate residual disease.
Recent news